<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070598</url>
  </required_header>
  <id_info>
    <org_study_id>Shengjing-LCG</org_study_id>
    <nct_id>NCT05070598</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer</brief_title>
  <official_title>A Prospective, Single-arm, Phase II Study of Camrelizumab Combined With Pyrotinib Maleate, Nab-paclitaxel and Tegafur Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the investigator's judgment, there are concomitant diseases that seriously&#xD;
      endanger the patient's safety, or affect the patient's completion of the study (such as&#xD;
      uncontrolled hypertension, diabetes, thyroid disease, etc.);&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR (Objective control rate)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The rate of CR and PR, determined using RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR (Disease control rate)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The rate of CR, PR plus SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Progression-Free survival)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>From the date Into this study (signed ICF) to tumor progression or death for any</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS(Overall survival)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>Baseline until death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>HER2-positive Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab Q3W d1 Pyrotinib d1-21 Nab-paclitaxel Q3W d1 Tegafur d1-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur</intervention_name>
    <description>Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle</description>
    <arm_group_label>Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - rious hepatic and renal impairment, organ function must meet the following requirements:&#xD;
        ANC ≥ 1.5 × 109/L; PLT ≥ 90 × 109/L; Hb ≥ 90g/L; TBIL ≤ 1.5 × ULN; ALT and AST ≤1.5 × ULN,&#xD;
        ALP ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN BUN and Cr ≤ 1 ×&#xD;
        ULN and cre&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  rious hepatic and renal impairment, organ function must meet the following&#xD;
             requirements: ANC ≥ 1.5 × 109/L; PLT ≥ 90 × 109/L; Hb ≥ 90g/L; TBIL ≤ 1.5 × ULN; ALT&#xD;
             and AST ≤1.5 × ULN, ALP ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤&#xD;
             5 × ULN BUN and Cr ≤ 1 × ULN and cre&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caigang Liu, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shengjing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nan Zhang, doctor</last_name>
    <phone>18940253560</phone>
    <email>zhangnan2515@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nan Niu, doctor</last_name>
    <phone>18940256668</phone>
    <email>niun@sj-hospital.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nan Zhang, doctor</last_name>
      <phone>18940253560</phone>
      <email>zhangnan2515@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Caigang Liu</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

